{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/AZN/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T05:21:31.404Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8355,"canonical_name":"ASTRAZENECA PLC","cik":"0000901832","uei":null,"lei":null,"duns":null,"ticker":"AZN"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"clinical":100,"sec":53},"count":100,"timeline":[{"ts":"2026-10-15","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive","security_title":"PHASE4","status":"NOT_YET_RECRUITING","accession_number":"NCT07876817","excerpt":"[\"Muscle-Invasive Bladder Cancer (MIBC)\"]","importance":25},{"ts":"2026-10-08","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07774403","excerpt":"[\"Bronchiectasis With Pseudomonas Aeruginosa Colonization\"]","importance":45},{"ts":"2026-10-08","kind":"clinical.trial","reporter":"AstraZeneca","title":"HER2-positive Metastatic Breast Cancer in Kazakhstan","security_title":null,"status":"RECRUITING","accession_number":"NCT07593196","excerpt":"[\"Metastatic Breast Cancer\"]","importance":25},{"ts":"2026-10-08","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treated in Everyday Medical Practice","security_title":null,"status":"RECRUITING","accession_number":"NCT07800754","excerpt":"[\"Gastric Cancer\",\"Gastroesophageal Junction Cancer\"]","importance":25},{"ts":"2026-10-06","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07612813","excerpt":"[\"Staphylococcus Aureus Bloodstream Infection\"]","importance":30},{"ts":"2026-10-05","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07619118","excerpt":"[\"Hypercholesterolaemia\"]","importance":60},{"ts":"2026-10-05","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-10-05","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008783","accession_number":"0001654954-26-008783","importance":30},{"ts":"2026-10-02","kind":"clinical.trial","reporter":"AstraZeneca","title":"Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07691970","excerpt":"[\"Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus\"]","importance":60},{"ts":"2026-10-02","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-10-02","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008760","accession_number":"0001654954-26-008760","importance":30},{"ts":"2026-10-01","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07775404","excerpt":"[\"Obesity\",\"Overweight\"]","importance":60},{"ts":"2026-10-01","kind":"clinical.trial","reporter":"AstraZeneca","title":"Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07851025","excerpt":"[\"Epithelial Ovarian Cancer\"]","importance":60},{"ts":"2026-10-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-10-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008739","accession_number":"0001654954-26-008739","importance":30},{"ts":"2026-10-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-10-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008741","accession_number":"0001654954-26-008741","importance":30},{"ts":"2026-09-30","kind":"clinical.trial","reporter":"AstraZeneca","title":"Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)","security_title":null,"status":"RECRUITING","accession_number":"NCT07633158","excerpt":"[\"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)\"]","importance":25},{"ts":"2026-09-29","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-29","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008615","accession_number":"0001654954-26-008615","importance":30},{"ts":"2026-09-29","kind":"clinical.trial","reporter":"AstraZeneca","title":"MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.","security_title":null,"status":"RECRUITING","accession_number":"NCT07607769","excerpt":"[\"Hepatocellular Carcinoma\"]","importance":25},{"ts":"2026-09-28","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07761117","excerpt":"[\"Heart Failure With Preserved Ejection Fraction (HFpEF)\",\"Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)\"]","importance":60},{"ts":"2026-09-28","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07622433","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-09-28","kind":"clinical.trial","reporter":"AstraZeneca","title":"Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07685600","excerpt":"[\"Healthy\"]","importance":30},{"ts":"2026-09-25","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07776509","excerpt":"[\"Obesity or Overweight\",\"Weight-Related Comorbidity\",\"With/Without Diabetes Mellitus, Type 2\"]","importance":60},{"ts":"2026-09-24","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07624305","excerpt":"[\"Renal Insufficiency, Chronic\"]","importance":60},{"ts":"2026-09-24","kind":"clinical.trial","reporter":"AstraZeneca","title":"Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist","security_title":"NA","status":"RECRUITING","accession_number":"NCT07718724","excerpt":"[\"Uncontrolled Asthma\"]","importance":25},{"ts":"2026-09-23","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-23","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008520","accession_number":"0001654954-26-008520","importance":30},{"ts":"2026-09-23","kind":"clinical.trial","reporter":"AstraZeneca","title":"BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy","security_title":null,"status":"RECRUITING","accession_number":"NCT07597993","excerpt":"[\"Breast Cancer\"]","importance":25},{"ts":"2026-09-22","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07751848","excerpt":"[\"Lupus Erythematosus, Systemic\"]","importance":60},{"ts":"2026-09-22","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07784270","excerpt":"[\"Obesity or Overweight\",\"Diabetes Mellitus, Type 2\"]","importance":60},{"ts":"2026-09-22","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07630714","excerpt":"[\"Systemic Lupus Erythematosus\"]","importance":45},{"ts":"2026-09-21","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07652658","excerpt":"[\"Idiopathic Pulmonary Fibrosis (IPF)\"]","importance":45},{"ts":"2026-09-21","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-21","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008476","accession_number":"0001654954-26-008476","importance":30},{"ts":"2026-09-21","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-21","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008478","accession_number":"0001654954-26-008478","importance":30},{"ts":"2026-09-18","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-18","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008438","accession_number":"0001654954-26-008438","importance":30},{"ts":"2026-09-18","kind":"clinical.trial","reporter":"AstraZeneca","title":"QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol","security_title":null,"status":"RECRUITING","accession_number":"NCT07787117","excerpt":"[\"Asthma\"]","importance":25},{"ts":"2026-09-17","kind":"clinical.trial","reporter":"AstraZeneca","title":"Study of Safety and PK of AZD0543 in Healthy Adults","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07824622","excerpt":"[\"Human Metapneumovirus Infection\"]","importance":30},{"ts":"2026-09-16","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07723833","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-09-16","kind":"clinical.trial","reporter":"AstraZeneca","title":"Observational Study of Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese Adults","security_title":null,"status":"RECRUITING","accession_number":"NCT07646600","excerpt":"[\"Dilated Cardiomyopathy\"]","importance":25},{"ts":"2026-09-15","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-15","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008367","accession_number":"0001654954-26-008367","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-15","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008369","accession_number":"0001654954-26-008369","importance":30},{"ts":"2026-09-14","kind":"clinical.trial","reporter":"AstraZeneca","title":"Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07816666","excerpt":"[\"Platinum-sensitive Relapsed Epithelial Ovarian Cancer\",\"Platinum-sensitive Relapsed Fallopian Tube Cancer\",\"Platinum-sensitive Relapsed Primary Peritoneal Cancer\"]","importance":60},{"ts":"2026-09-14","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-14","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008323","accession_number":"0001654954-26-008323","importance":30},{"ts":"2026-09-14","kind":"clinical.trial","reporter":"AstraZeneca","title":"Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations","security_title":null,"status":"RECRUITING","accession_number":"NCT07654855","excerpt":"[\"Transthyretin Amyloidosis\",\"Transthyretin Amyloidosis With Cardiomyopathy\",\"Transthyretin Amyloidosis With Polyneuropathy\"]","importance":25},{"ts":"2026-09-10","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07619131","excerpt":"[\"Hypercholesterolaemia\"]","importance":60},{"ts":"2026-09-10","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07812077","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-09-09","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07662213","excerpt":"[\"Type 2 Diabetes Mellitus\"]","importance":60},{"ts":"2026-09-09","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07667803","excerpt":"[\"Weight Management\"]","importance":60},{"ts":"2026-09-09","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07753993","excerpt":"[\"Chronic Kidney Disease\"]","importance":60},{"ts":"2026-09-09","kind":"clinical.trial","reporter":"AstraZeneca","title":"TROP2 NMR Concordance Study","security_title":null,"status":"RECRUITING","accession_number":"NCT07624318","excerpt":"[\"Lung Cancer\"]","importance":25},{"ts":"2026-09-08","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07647328","excerpt":"[\"ER-Positive HER2-Negative Breast Cancer\"]","importance":60},{"ts":"2026-09-08","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-08","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008150","accession_number":"0001654954-26-008150","importance":30},{"ts":"2026-09-08","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-08","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008172","accession_number":"0001654954-26-008172","importance":30},{"ts":"2026-09-08","kind":"sec.insider.a","reporter":"Sharma Mani","title":"See Remarks","shares":1,"price_per_share":162.6,"usd_value":163,"security_title":"Ordinary Shares","importance":15.0001626},{"ts":"2026-09-04","kind":"clinical.trial","reporter":"AstraZeneca","title":"Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07754331","excerpt":"[\"Kidney Failure\"]","importance":30},{"ts":"2026-09-04","kind":"clinical.trial","reporter":"AstraZeneca","title":"Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial Intelligence","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07617636","excerpt":"[\"Lung Cancer\"]","importance":25},{"ts":"2026-09-03","kind":"clinical.trial","reporter":"AstraZeneca","title":"CHARM Hepatocellular Carcinoma MEA Study","security_title":null,"status":"RECRUITING","accession_number":"NCT07650773","excerpt":"[\"HepatoCellular Carcinoma\"]","importance":25},{"ts":"2026-09-02","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07662135","excerpt":"[\"Type 2 Diabetes Mellitus\",\"Type 2 Diabetes With Chronic Kidney Disease\"]","importance":60},{"ts":"2026-09-01","kind":"clinical.trial","reporter":"AstraZeneca","title":"Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07610837","excerpt":"[\"Liver Fibrosis\",\"Hepatic Cirrhosis\"]","importance":45},{"ts":"2026-09-01","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)","security_title":"PHASE1,PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07717840","excerpt":"[\"RSV Respiratory Syncytial Virus\"]","importance":45},{"ts":"2026-09-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007983","accession_number":"0001654954-26-007983","importance":30},{"ts":"2026-09-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007986","accession_number":"0001654954-26-007986","importance":30},{"ts":"2026-09-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007988","accession_number":"0001654954-26-007988","importance":30},{"ts":"2026-09-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007990","accession_number":"0001654954-26-007990","importance":30},{"ts":"2026-09-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007992","accession_number":"0001654954-26-007992","importance":30},{"ts":"2026-09-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008040","accession_number":"0001654954-26-008040","importance":30},{"ts":"2026-09-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-09-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-008042","accession_number":"0001654954-26-008042","importance":30},{"ts":"2026-08-31","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07662109","excerpt":"[\"Type 2 Diabetes Mellitus\"]","importance":60},{"ts":"2026-08-31","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07662044","excerpt":"[\"Type 2 Diabetes Mellitus\"]","importance":60},{"ts":"2026-08-27","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07681596","excerpt":"[\"Relapsed or Refractory Multiple Myeloma\"]","importance":45},{"ts":"2026-08-27","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-08-27","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007894","accession_number":"0001654954-26-007894","importance":30},{"ts":"2026-08-27","kind":"clinical.trial","reporter":"AstraZeneca","title":"Tezepelumab CRSwNP Real World Study (CREW Study)","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07790198","excerpt":"[\"Chronic Rhinosinusitis With Nasal Polyps\"]","importance":25},{"ts":"2026-08-26","kind":"clinical.trial","reporter":"AstraZeneca","title":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07611110","excerpt":"[\"Metastatic Castration-resistant Prostate Cancer\"]","importance":60},{"ts":"2026-08-26","kind":"clinical.trial","reporter":"AstraZeneca","title":"Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM","security_title":null,"status":"RECRUITING","accession_number":"NCT07690436","excerpt":"[\"Transthyretin Amyloid Cardiomyopathy\"]","importance":25},{"ts":"2026-08-25","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07784725","excerpt":"[\"Obesity or Overweight\"]","importance":60},{"ts":"2026-08-25","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-08-25","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007840","accession_number":"0001654954-26-007840","importance":30},{"ts":"2026-08-25","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies","security_title":null,"status":"RECRUITING","accession_number":"NCT07606066","excerpt":"[\"Type 2 Diabetes\"]","importance":25},{"ts":"2026-08-25","kind":"clinical.trial","reporter":"AstraZeneca","title":"China Glomerulonephritis Kidney Transplant Recipient Cohort: A Prospective Multicenter Observational Study","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07783737","excerpt":"[\"Glomerulonephritis Kidney Transplant\"]","importance":25},{"ts":"2026-08-24","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07783308","excerpt":"[\"Hepatic Impairment\"]","importance":30},{"ts":"2026-08-19","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-08-19","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007742","accession_number":"0001654954-26-007742","importance":30},{"ts":"2026-08-17","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-08-17","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007677","accession_number":"0001654954-26-007677","importance":30},{"ts":"2026-08-17","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-08-17","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007679","accession_number":"0001654954-26-007679","importance":30},{"ts":"2026-08-17","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-08-17","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007681","accession_number":"0001654954-26-007681","importance":30},{"ts":"2026-08-14","kind":"clinical.trial","reporter":"AstraZeneca","title":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07764978","excerpt":"[\"Newly Diagnosed Multiple Myeloma\"]","importance":60},{"ts":"2026-08-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07760519","excerpt":"[\"Carcinoma, Non-Small-Cell Lung\"]","importance":25},{"ts":"2026-08-08","kind":"sec.insider.p","reporter":"Sharma Mani","title":"See Remarks","shares":20.233,"price_per_share":160.57,"usd_value":3249,"security_title":"Ordinary Shares","importance":50.00324881281},{"ts":"2026-08-04","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07664553","excerpt":"[\"Type 2 Diabetes Mellitus\"]","importance":60},{"ts":"2026-08-04","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.","security_title":null,"status":"RECRUITING","accession_number":"NCT07743944","excerpt":"[\"Breast Cancer\"]","importance":25},{"ts":"2026-08-03","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-08-03","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007166","accession_number":"0001654954-26-007166","importance":30},{"ts":"2026-08-03","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-08-03","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007169","accession_number":"0001654954-26-007169","importance":30},{"ts":"2026-07-31","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-07-31","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-007050","accession_number":"0001654954-26-007050","importance":30},{"ts":"2026-07-30","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07735637","excerpt":"[\"Newly Diagnosed Multiple Myeloma (NDMM)\"]","importance":60},{"ts":"2026-07-27","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-07-27","url_slug":"/sec/cik-0000901832/6-k/0001104659-26-086846","accession_number":"0001104659-26-086846","importance":30},{"ts":"2026-07-27","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-07-27","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-006895","accession_number":"0001654954-26-006895","importance":30},{"ts":"2026-07-27","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-07-27","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-006897","accession_number":"0001654954-26-006897","importance":30},{"ts":"2026-07-23","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-07-23","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-006803","accession_number":"0001654954-26-006803","importance":30},{"ts":"2026-07-22","kind":"clinical.trial","reporter":"AstraZeneca","title":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07720284","excerpt":"[\"High-risk Muscle Invasive Urothelial Carcinoma\"]","importance":60},{"ts":"2026-07-22","kind":"clinical.trial","reporter":"AstraZeneca","title":"The DEBATE Study \"DEvelopment of Endotype-based Biomarkers for the Monitoring of Greek pATiEnts With CRSwNP\"","security_title":null,"status":"RECRUITING","accession_number":"NCT07663409","excerpt":"[\"CRSwNP or CRSsNP Patients\"]","importance":25},{"ts":"2026-07-17","kind":"clinical.trial","reporter":"AstraZeneca","title":"Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07711002","excerpt":"[\"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)\"]","importance":60},{"ts":"2026-07-14","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07608354","excerpt":"[\"Transthyretin Amyloid Cardiomyopathy (ATTR-CM)\"]","importance":45},{"ts":"2026-07-14","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-07-14","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-006637","accession_number":"0001654954-26-006637","importance":30},{"ts":"2026-07-14","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)","security_title":"NA","status":"RECRUITING","accession_number":"NCT07613424","excerpt":"[\"Non-Small Cell Lung Cancer\"]","importance":25},{"ts":"2026-07-14","kind":"clinical.trial","reporter":"AstraZeneca","title":"SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07701070","excerpt":"[\"Advanced Breast Cancer\"]","importance":25},{"ts":"2026-07-09","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-07-09","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-006554","accession_number":"0001654954-26-006554","importance":30}]}